Kanabo Group Past Earnings Performance
Past criteria checks 0/6
Kanabo Group has been growing earnings at an average annual rate of 21.9%, while the Pharmaceuticals industry saw earnings growing at 0.5% annually. Revenues have been growing at an average rate of 173.7% per year.
Key information
21.9%
Earnings growth rate
30.0%
EPS growth rate
| Pharmaceuticals Industry Growth | 14.1% |
| Revenue growth rate | 173.7% |
| Return on equity | -33.8% |
| Net Margin | -571.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Kanabo Group makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 1 | -5 | 4 | 1 |
| 31 Mar 23 | 1 | -6 | 4 | 1 |
| 31 Dec 22 | 1 | -7 | 5 | 1 |
| 30 Sep 22 | 0 | -6 | 4 | 0 |
| 30 Jun 22 | 0 | -6 | 4 | 0 |
| 31 Mar 22 | 0 | -5 | 3 | 0 |
| 31 Dec 21 | 0 | -5 | 3 | 0 |
| 30 Sep 21 | 0 | -4 | 2 | 0 |
| 30 Jun 21 | 0 | -3 | 1 | 0 |
| 31 Mar 21 | 0 | -2 | 1 | 0 |
| 31 Dec 20 | 0 | -1 | 0 | 0 |
Quality Earnings: KNB is currently unprofitable.
Growing Profit Margin: KNB is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if KNB's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare KNB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: KNB is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.7%).
Return on Equity
High ROE: KNB has a negative Return on Equity (-33.81%), as it is currently unprofitable.